Equol and daidzein decrease migration, invasion and matrix metalloproteinase (MMPs) gene expression in prostate cancer cell lines, DU-145 and PC-3 / Equol y daidzeina disminuyen la migración, invasión y la expresión génica de metaloproteinasa de la matriz(MMPs) en las líneas celulares prostáticas cancerosas DU-145 y PC-3

This search is focused on the study of diet compounds that may have any potential chemopreventive effect against cancer. Some compounds that fulfill this requirement are phytoestrogens. Among them we find genistein (1), the most studied, daidzein (2) and equol (3) (figure 1). To compare the sensitivities of different prostate cancer cells to phytoestrogen treatment, sulphorhodamine B dye assay was performed to determine cell viability. DU-145 and PC-3 prostate cancer cell lines treated with various doses of phytoestrogen (0-12.5-25-50 and 100 μM) for different times (24, 48 and 72h). For cell invasion or migration assay cells were seeded in a Transwell chamber with or without coating Matrigel respectively. DU-145 and PC-3 cells were treated previously with phytoestrogen (50 μM) for 24h. The study showed that equol, daidzein and genistein inhibited migration and invasion in prostate cancer cell lines. Moreover, we analyzed the effects of phytoestrogens in MMP-2 and MMP-9 mRNA expression by RT-PCR. The results indicated that equol, daidzein and genistein diminished the expression of MMP-2 and MMP-9 in a cell-dependent manner. Our data suggested that equol, daidzein and genistein inhibited migration and invasion in prostate cancer cell lines. Moreover, the results also suggest that down-regulation of MMP-2 and MMP- 9 might be involved in the inhibition of invasion of PC-3 and DU-145 cells after genistein, daidzein and equol treatment.

Este trabajo se centra en el estudio de los compuestos de dieta que pueden tener potencial efecto quimiopreventivo contra el cáncer. Algunos de estos compuestos son los fitoestrógenos. Entre ellos encontramos la genisteína (1), el más estudiado, la daidzeína (2) y el equol (3) (figura 1). Para comparar el efecto de estos fitoestrogenos sobre las líneas celulares de cáncer de próstata, DU-145 y PC-3, se utilizó el ensayo de sulforodamina B para determinar la viabilidad celular tras los tratamientos con diferentes concentraciones de fitoestrógenos (0-12.5-25-50-100 μM) durante diferentes tiempos (24, 48, 72 h). Para analizar el efecto sobre la migración celular, las células DU-145 y PC-3 fueron tratadas previamente con una concentración de fitoestrógrno (50 μM) durante 24 horas y sembradas en una cámara Transwell sin recubrir. El estudio mostró que el equol, daidzeína y genisteína inhibió en MMP-2 y MMP-9 expresiones de genes en líneas celulares de cáncer de próstata, la PC-3 y DU-145. Los resultados indicaron que la daidzeína disminuyó la expresión de MMP- 2 y MMP-9 en DU-145 células. Nuestros datos sugieren que equol, daidzeína y genisteína inhiben la migración y la invasión de líneas celulares de cáncer de próstata.

Daidzein-estrogen interaction in the rat uterus and its effect on human breast cancer cell growth.

Sex hormone replacement therapy provides several advantages in the quality of life for climacteric women. However, estrogen-induced cell proliferation in the uterus and mammary gland increases the risk of cancer development in these organs. The lower incidence of mammary cancer in Asian women as compared with Western women has been attributed to high intake of soy isoflavones, including genistein. We have previously shown that genistein induces an estradiol-like hypertrophy of uterine cells, but does not induce cell proliferation, uterine eosinophilia, or endometrial edema. It also inhibits estradiol-induced mitosis in uterine cells and hormone-induced uterine eosinophilia and endometrial edema. Nevertheless, genistein stimulates growth of human breast cancer cells in culture; therefore, it is not an ideal estrogen for use in hormone replacement therapy (HRD). The present study investigated the effect of another soy isoflavone, daidzein (subcutaneous, 0.066 mg/kg body weight), in the same animal model, and its effect on responses induced by subsequent treatment (1 h later) with estradiol-17ß (E(2); subcutaneous, 0.33 mg/kg body weight). In addition, we investigated the effects of daidzein (1 µg/mL) or E(2) on the growth of human breast cancer cells in culture. Results indicate that daidzein stimulates growth of breast cancer cells and potentiates estrogen-induced cell proliferation in the uterus. We suggest caution for the use of daidzein or formulas containing this compound in HRD. Future research strategies should be addressed in the search for new phytoestrogens that selectively inhibit cell proliferation in the uterus and breast.

Genistein selectively inhibits estrogen-induced cell proliferation and other responses to hormone stimulation in the prepubertal rat uterus.

Sex hormone replacement therapy helps improve quality of life in climacteric women. However, estrogen-induced cell proliferation in the uterus and mammary gland increases the risk for cancer in these organs. The lower incidence of mammary cancer in Asian women than in western women has been attributed to high intake of soy isoflavones, including genistein. Our previous work in the prepubertal rat uterus model showed that genistein (0.5 mg/kg body weight subcutaneously) caused an estradiol-like hypertrophy in myometrial and uterine luminal epithelial cells and an increase in RNA content in luminal epithelium; however, it did not induce cell proliferation, uterine eosinophilia, or endometrial edema. The present study investigated, in the same animal model, the effect of genistein administration (0.5 mg/kg body weight subcutaneously) before treatment with estradiol-17ß (0.33 mg/kg body weight subcutaneously) on uterine responses that were not induced by genistein. Pretreatment with this phytoestrogen completely inhibited estradiol-induced mitoses in uterine luminal epithelium, endometrial stroma, and myometrium and partially inhibited estradiol-induced uterine eosinophilia and endometrial edema. These findings indicate that genistein protects against estrogen-induced cell proliferation in the uterus and suggest that future studies should investigate the possibility of using this agent to decrease the risk for uterine cancer after hormone replacement therapy in climacteric women.

Biological activity of genistein and soy extracts: selective induction of some but not all estrogenic responses in the prepubertal rat uterus / Actividad biológica de Genisteína y extractos de soya: inducción selectiva de algunas pero no todas las respuestas estrogénicas en el útero de la rata prepúber

The existence of multiple kinds of estrogen receptors (ERs), involved in independent groups of responses, allows their dissociation and opens the possibility to selectively induce beneficial responses but not those considered at risk (cell proliferation). Based on the low hormone-dependent cancer mortality in Eastern Asia, attributed to high dietary intake of estrogenic isoflavones, we investigated whether genistein (G) or soybean extracts (S) selectively induce some, but not all estrogenic responses in the rat uterus, comparing its activity to that of estradiol-17 (E2). Prepubertal rats were treated with E2, G, concentrated S (Sc), diluted S (Sd), or vehicle, and uterine responses to estrogen were evaluated. Luminal epithelial and myometrial cell hypertrophy, and luminal epithelial RNA increase, were induced by E2, G or S. Uterine eosinophilia, endometrial edema and proliferation of 4 uterine cell-types were induced by E2 only. Results reveal that G and S induce some responses to estrogen but not others, suggesting their use as agents not displaying carcinogenic risk.

La existencia de múltiples tipos de receptores de estrógeno (ERs), involucrados en el desarrollo de grupos independientes de respuestas a estrógeno, permite su disociación y abre la posibilidad de inducir en forma selectiva respuestas benéficas pero no aquellas consideradas de riesgo (proliferación celular). Basado en la baja mortalidad por cánceres hormono-dependientes en el Este Asiático, atribuidos a una alta ingesta dietaria de isoflavonas estrogénicas, nosotros investigamos si la genisteína (G) o extractos de soja (S) inducen en forma selectiva algunas, pero no todas, las respuestas estrogénicas en el útero de rata, comparando su actividad con la del estradiol-17beta (E2). Ratas prepuberales fueron tratadas con E2, G, S concentrado (Sc), S diluido (Sd) o vehículo, y las respuestas estrogénicas en el útero fueron evaluadas. Las hipertrofias celulares en epitelio luminal y miometrio, y el aumento de ARN en células del epitelio luminal fueron inducidas por E2, G o S. La eosinofilia uterina, el edema en estroma endometrial y la proliferación de 4 tipos celulares uterinos fueron inducidos sólo por E2. Los resultados revelan que G y S inducen algunas respuestas estrogénicas pero no otras, sugiriendo su uso terapéutico como agentes estrogénicos que no presentan riesgo de cáncer.

¿Es posible encontrar un fitoestrógeno para la terapia de reemplazo hormonal, que disminuya el riesgo de cáncer?: tema de Proyecto Anillos de Investigación del Programa Bicentenario en Ciencia y Tecnología / Is it possible to find a phytoestrogen for hormone replacement therapy, decreasing cancer risk?: subject of Research Team Grant in Science and Technology from the Bicentennial Program in Science and Technology

Se describe una nueva línea de investigación que tiene como objetivo investigar principios activos presentes en especies vegetales chilenas, para identificar alguna(s) que produzcan los efectos farmacológicos deseables para su uso como terapia de reemplazo hormonal en mujeres peri o postmenopáusicas, pero que no aumenten, o incluso disminuyan, el riesgo de desarrollar cáncer mamario o endometrial. Esta posibilidad se basa en el hallazgo previo de nuestro equipo de investigadores de un nuevo tipo de receptores estrogénicos responsables de respuestas estrogénicas no genómicas y de nuestro hallazgo de diferencias entre los receptores estrogénicos citosólico-nucleares clásicos de los diferentes tipos celulares uterinos. Si existiera, como anteriormente se creía, un solo tipo de receptor de estrógenos, no sería posible el desarrollo de este nuevo fármaco estrogénico selectivo que buscamos, pues todos los receptores tendrían la misma afinidad por este agente, el que en consecuencia, induciría todas las respuestas a la estimulación estrogénica (incluyendo aquellas que deseamos prevenir, como las que presentan riesgo de desarrollo de cáncer), o que actuaría como antiestrógeno, antagonizando todas las respuestas a los estrógenos en el útero.

A new research line aimed at the investigation of active agents from Chilean plant species is described. The purpose is to indentify those agents inducing expected pharmacological effects in a hormone replacement therapy in peri- or post-menopausal women, but not increasing, or even decreasing, the risk for development of mammary or endometrial cancer. This possibility is based on previous findings from our research team of a new kind of estrogen receptors, responsible of non-genomic responses to estrogen, and our finding of differences between the classical cytosol-receptor estrogen receptors from the different uterine cell-types. If there exists one kind of estrogen receptors only in the uterus, as it was formerly accepted, then it is not possible to develop the selective estrogenic drug we search for, because all receptors would display the same affinity for this agent; therefore, it would induce all responses to estrogen stimulation (including those we wish to prevent, such as those presenting risk of cancer development), or would act as antiestrogen, antagonizing all responses to estrogen in the uterus.

Voltammetric behavior of zaleplon and its differential pulse polarographic determination in capsules.

In this work both the electrochemical behavior and the analysis of the hypnotic pyrazolopyrimidine derivative zaleplon were studied. Zaleplon in ethanol-0.1M Britton Robinson buffer solution (30-70) showed 2 irreversible, well-defined cathodic responses in the pH range of 2-12 using differential pulse polarography (DPP), tast polarography, and cyclic voltammetry. From chronocoulometric studies, it was possible to conclude that one electron was transferred in each reduction peak or wave. For analytical purposes, the DPP technique working at pH 4.5 for peak I was selected, which exhibited adequate repeatability, reproducibility, and selectivity. The recovery was 99.97 +/- 1.52%, and the detection and quantitation limits were 5.13 x 10(-7)M and 1.11 x 10(-6)M, respectively. The DPP method was applied successfully to the individual assay of capsules in order to verify the content uniformity of zaleplon. Treatment of the sample is not required because the excipients do not interfere, the method is not time consuming, and it is less expensive than column liquid chromatography.

Development and validation of an UV derivative spectrophotometric determination of Losartan potassium in tablets.

Development and validation of an analytical UV derivative spectrophotometric method to quantify Losartan potassium used as a single active principle in pharmaceutical forms were done. Pharmacopeias have not yet provided an official method for its quantification. A study was carried out of all the parameters established by USP XXIV to validate an analytical method for a solid pharmaceutical form, i.e. linearity, range, accuracy, precision and specificity. All these parameters were found in accordance with the acceptance criteria of Comité de Guías Oficiales de Validación de la Dirección General de Control de Insumos para la Salud de México. Based on the spectrophotometric characteristics of Losartan potassium, a signal at 234 nm of the first derivative spectrum (1D234) was found adequate for quantification. The linearity between signal 1D234 and concentration of Losartan potassium in the range of 4.00-6.00 mg l(-1) in aqueous solutions presents a square correlation coefficient (r2) of 0.9938. The mean recovery percentage was 100.7+/-1.1% and the precision expressed as relative standard deviation (R.S.D.) 0.88%. In addition, the proposed method is simple, easy to apply, low-cost, does not use polluting reagents and requires relatively inexpensive instruments. Then, it is a good alternative to existing methods for determining Losartan potassium in tablets provided that the pharmaceutical dosage form does not contain hydrochlorothiazide as second drug.

Constituents and biological activities from Muehlenbeckia hastulata.

Muehlenbeckia hastulata (J. E.Sm.) Johnst. used mainly for its abortive properties was found active for oxytoxic and analgesic activities in a biological activity screening (oxytoxic, analgesic, antimicrobial, cytotoxic and xanthine oxidase assay). Epicatechin, emodin-8-glycoside and rutin were isolated from the aerial part and the root of the plant.